Key result
Eicosapentaenoic acid (EPA) use was not associated with a reduced risk of new-onset depression among patients with hyperlipidemia compared to other lipid-lowering medications (HR 0.89; 95% CI 0.67-1.20).
Why the study?
Does eicosapentaenoic acid (EPA) prevent new onset of depression in Japanese patients with hyperlipidemia?
Cohort (n=76,561)
Does eicosapentaenoic acid (EPA) prevent new onset of depression in Japanese patients with hyperlipidemia?
Answers are grounded in this paper and cite their sources.
EPA medication intake does not appear to prevent the new onset of depression in Japanese patients with hyperlipidemia.
A number of preclinical and clinical studies have suggested that omega-3 fatty acids have a prophylactic effect against depression. The aim of this study was to explore the effect of eicosapentaenoic acid (EPA) on development of depression among Japanese patients with hyperlipidemia. This was a 3-year follow up study based on medical claims data obtained from Japan Medical Data Center. A total of 76,561 patients were eligible for the final analyses. The exposure group included EPA drug users categorized into 2 groups based on adherence to EPA using the Medication Possession Ratio (MPR) with a cutoff of 80%. The control group (non-EPA group) consisted of subjects taking lipid-lowering medications other than EPA. A Cox proportional hazard model was used to evaluate the association between EPA drug use and the development of depression. Over 3 year-follow up, 1319 (1.7%) patients developed depression. In the multivariate Cox proportional hazard model, no association was found between depression and EPA drug use in the MPR ≥80% group (HR:0.89, 95%CI: 0.67 to 1.20) or MPR < 80% group (HR:1.00, 95%CI: 0.73 to 1.37) compared with the non-EPA group. No convincing evidence was found to support the association between EPA and risk of depression before and after adjusting for age, gender, and comorbidity.
No takes yet. Share an insight, caveat, or question.
Song et al. (2017) conducted a cohort in Hyperlipidemia (n=76,561). Eicosapentaenoic acid (EPA) vs. Lipid-lowering medications other than EPA was evaluated on Development of depression (HR 0.89, 95% CI 0.67 to 1.20). Eicosapentaenoic acid (EPA) use was not associated with a reduced risk of new-onset depression among patients with hyperlipidemia compared to other lipid-lowering medications (HR 0.89; 95% CI 0.67-1.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: